anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sirtuin 7 (SIRT7) is a member of the mammalian family of nicotinamide adenine dinucleotide (NAD+)-dependent histone/protein deacetylases, known as sirtuins. It acts as a potent oncogene in numerous malignancies, but the molecular mechanisms employed by SIRT7 to sustain lung cancer progression remain largely uncharacterized. We demonstrate that SIRT7 exerts oncogenic functions in lung cancer cells by destabilizing the tumor suppressor alternative reading frame (ARF). SIRT7 directly interacts with ARF and prevents binding of ARF to nucleophosmin, thereby promoting proteasomal-dependent degradation of ARF. We show that SIRT7-mediated degradation of ARF increases expression of protumorigenic genes and stimulates proliferation of non-small-cell lung cancer (NSCLC) cells both in vitro and in vivo in a mouse xenograft model. Bioinformatics analysis of transcriptome data from human lung adenocarcinomas revealed a correlation between SIRT7 expression and increased activity of genes normally repressed by ARF. We propose that disruption of SIRT7-ARF signaling stabilizes ARF and thus attenuates cancer cell proliferation, offering a strategy to mitigate NSCLC progression.
In this single-arm prospective BREAST-ART study breast cancer patients with an indication for postoperative radiotherapy will be treated according to the Dutch and institutional guidelines. Target volumes will be the whole breast, chest wall, axillary levels, tumor bed boost and partial breast irradiation on the right side and left side with a deep inspiration breath hold technique. Robust templates are developed for offline and online treatment planning with an IMRT tangential multiple-beam setup. A simulation of the online adaptive workflow is performed in breast cancer patients already treated on the Ethos-linac with the standard offline adaptive workflow. Patients will be treated following the online adaptive workflow delivered on the Ethos-Linac. Patient experience will be evaluated using an in-house developed questionnaires after the first and last fraction, scoring treatment satisfaction on a 4-point Likert scale. Furthermore, all dosimetric data, volume details, DICOM images and the time spend on all parts of the online adaptive workflow will be evaluated.
A satellite system operates at altitudes between 180 km and 350 km relying on vehicles including an engine to counteract atmospheric drag to maintain near-constant orbit dynamics. The system operates at altitudes that are substantially lower than traditional satellites, reducing size, weight and cost of the vehicles and their constituent subsystems such as optical imagers, radars, and radio links. The system can include a large number of lower cost, mass, and altitude vehicles, enabling revisit times substantially shorter than previous satellite systems. The vehicles spend their orbit at low altitude, high atmospheric density conditions that have heretofore been virtually impossible to consider for stable orbits. Short revisit times at low altitudes enable near-real time imaging at high resolution and low cost. At such altitudes, the system has no impact on space junk issues of traditional LEO orbits, and is self-cleaning in that space junk or disabled craft will de-orbit.
This group received mothers own milk with fortification (human milk fortification, HMF) throughout the 4 month intervention period. Randomisation for group 1 og group 2. Enfamil HM fortifier, Mead Johnson.
BACKGROUND: Adult idiopathic occlusion of foramen of Monro (AIOFM) is a rare condition that results in hydrocephalus, and bilateral presentation is even rarer. Here we report a case of idiopathic bilateral stenosis of the foramen of Monro in an adult patient and performed a systematic literature review on the current treatment options and outcomes.
METHODS: We performed a systematic review of SCOPUS, Science Direct, and PubMed databases in accordance with PRISMA guidelines. Data on demographics, clinical presentation, imaging findings, type of AIOFM, treatment, and outcomes were collected.
RESULTS: A total of 22 cases of bilateral AIOFM were identified in the literature, including ours. The median age was 38.5 years (range: 20-53), with no sex predilection. The most common presenting symptoms were headache (n=16, 73%) and vomiting (n=10, 45%). There were 9 cases of Type 1 AIOFM (stenosis) and 13 cases of Type 2 (membrane occlusion). Majority of patients underwent surgical treatment, mostly endoscopic unilateral foraminoplasty and septostomy (59%), followed by ventriculoperitoneal shunt insertion (31%). One patient underwent medical management only to alleviate her presenting symptoms (seizures). The overall outcome was good for majority of patients at a median follow-up of 6 months.
CONCLUSION: Bilateral AIOFM is a rare condition that may easily be missed, so neurosurgeons should be cognizant of this disease entity. Identification of the type of AIOFM may guide surgical decision-making. Treatment options include neuroendoscopic procedures such as septostomy and foraminoplasty, and ventriculoperitoneal shunt insertion.
Irinotecan (CPT-11) is a commonly prescribed chemotherapeutic for the treatment of colon cancer. Unfortunately, acute and delayed diarrhea are prominent side effects of CPT-11 use, and this limits its therapeutic potential. The curative effect of Huangqin decoction (HQD) on chemotherapy-induced diarrhea has been proven. This study investigated the efficacy of the components of HQD (baicalein, baicalin, and paeoniflorin) on CPT-11-induced diarrhea and their underlying mechanisms. Baicalein was found to be the most effective component in improving CPT-11-induced enterotoxicity by intestinal permeability test, ELISA, fluorescence co-localization, and IHC. The combination of baicalin, baicalin and paeoniflorin can obtain similar therapeutic effect to that of HQD. Mendelian randomization analysis, 16 s rRNA sequencing, and fluorescence imaging revealed that baicalein and baicalin significantly inhibited β-glucuronidase (β-GUS) activity. Bacterial abundance analysis and scanning electron microscopy showed that baicalein inhibited the proliferation of Escherichia coli by destroying its cell wall. The molecular dynamics and site-directed mutagenesis results revealed the structural basis for the inhibition of β-GUS by baicalein and baicalin. The results above provide a new idea for the development of drug therapy for adjuvant chemotherapy and theoretical guidance for the optimization of molecular structure targeting β-GUS.
The invention discloses a traditional Chinese medicine preparation for treating rhinitis and nasosinusitis and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following crude drugs in parts by weight: 10-15 parts of asarum, 5-10 parts of monkshood, 15-20 parts of radix rehmanniae praeparata, 5-10 parts of radix paeoniae alba, 5-10 parts of pseudo-ginseng, 5-10 parts of safflower carthamus, 5-10 parts of butterflybush flower, 15-20 parts of periostracum cicada, 15-20 parts of honey-fried licorice root, 10-15 parts of herba lycopi, 10-15 parts of radix angelicae, 5-10 parts of garden burnet, 5-10 parts of scutellaria baicalensis, 5-10 parts of mint, 15-20 parts of calcined gypsum, 1-5 parts of cocklebur fruit, 1-5 parts of magnolia flower, 1-5 parts of herba centipedae, 15-20 parts of chrysanthemum, 1-5 parts of rhizoma cimicifugae and 10-15 parts of liquorice. The crude drugs are added with water, heated to be boiled with high heat, decocted with gentle heat, filtered and decocted for three times, and the filtrate is mixed to obtain the traditional Chinese medicine preparation. The traditional Chinese medicine preparation comprises the crude drugs in compatibility, is capable of clearing away heat and toxic materials, warming lung and resolving dampness, tonifying spleen and benefiting qi and clearing the nasal cavity, quick in efficacy and excellent in curative effect. Rhinitis and nasosinusitis do not relapse after being cured through the traditional Chinese medicine preparation. The cure rate is 92% and the total effective rate is 99%.
Patients receive oral thalidomide once daily for 1 year in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may receive 1 additional year of therapy.
This is a collaborative study between the Institute for Exercise and Environmental Medicine (IEEM; Texas Health Resources/University of Texas Southwestern medical Center) and VA North Texas Healthcare System (VANTHCS). The overall study was conceptualized and initiated by Dr. Qi Fu and her research team at the IEEM. IEEM researchers will be responsible for recruitment of non-veteran women without a diagnosis of PTSD, physiological assessments, and the lifestyle modification intervention. VANTHCS researchers will be responsible for recruitment of women veterans with PTSD and psychological assessments. The procedures taking place at VANTHCS (recruitment of women Veterans with PTSD and psychological assessments) will fall under a separate study (overseen by VANTCHS IRB and RDC) and will not include the procedures and intervention that will take place at the IEEM (which will be overseen by a separate IRB). Data will be shared between the sites per data sharing agreement. This clinical trials entry reflects the VANTHCS study. Outcome measures gathered by the IEEM research team are included in this entry due to the data sharing agreement.
In the control arm, students will have one 3-hour regular session of bedside learning of emergency airway management. The PI will demonstrate endotracheal intubation using video laryngoscope (C-MAC®) and other AGPs, such as bag-valve-mask ventilation on a manikin in the resuscitation room in front of the students there.
Tablet formulated as ferrous fumarate, 30 mg. Given once daily for 6 months.
PURPOSE: A composition containing complex crude drug extract is provided to effectively prevent and treat cardiovascular diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating cardiovascular diseases contains complex crude drug extract as an active ingredient, including Rhynchosia Nulubilis and Dendranthema indicum (L.) mixed in a weight ratio of 1: 0.1-10(w/w%). The Rhynchosia Nulubilis is defatted or hydrolysate thereof. The extract is isolated using water, methanol, ethanol, butanol, or a mixture solvent thereof. A health functional food for preventing and treating cardiovascular diseases contains the complex crude drug extract as an active ingredient. The health functional food is manufactured in the form of a tablet, capsule, powder, granule, liquid, and pill.
Homeodomain transcription factor A9 (HOXA9) is a member of the HOX cluster family of transcription factors that are crucially involved in embryo implantation, morphogenesis, body axis development, and endothelial cell differentiation. Despite numerous reports on its aberrant expression in a few malignancies, the molecular and functional complexity of HOXA9 across cancers remains obscure. We aimed to analyze the dynamic role of HOXA9 across cancers by identifying, analyzing, and understanding its multiple modes of regulation and functional implications and identifying possible therapeutic avenues. We conducted a comprehensive analysis to determine the role of HOXA9 across cancers. This approach involved the integration of large-scale datasets from public repositories such as the Genomic Data Commons, specifically the Cancer Genome Atlas (GDC-TCGA), across 33 different cancer types. The multiple modes of HOXA9 regulation by genetic and epigenetic factors were determined using online tools, which comprised experimentally validated observations. Furthermore, downstream pathways were identified by predicting the targets of HOXA9 and by performing functional enrichment analysis. We also assessed the clinical significance of HOXA9 in terms of prognosis and stage stratification. This study evaluated the correlation between HOXA9 and tumor-infiltrating molecules and discussed its association with therapeutically approved antineoplastic drugs. HOXA9 was significantly upregulated in 9 tumors and downregulated in 2 cancers. The deregulation of HOXA9 is primarily attributed to epigenetic factors, including promoter DNA methylation and noncoding RNAs (ncRNAs). The HOXA9 transcription factor interacts with PBX/MEIS cofactors and regulates multiple genes involved in cancer-associated EMT, autophagy, the cell cycle, metabolic pathways, Wnt signaling, TGF-β signaling, the AMPK pathway, PI3K/AKT signaling, and NF-κB signaling, thereby establishing control over downstream mechanisms. Differential expression in various clinical stages across cancers was shown to have prognostic significance and to be correlated with tumor-infiltrating immune molecules. The assessment of the correlation of HOXA9 expression with approved antineoplastic drugs revealed that targeting HOXA9 could be the most reliable strategy for preventing cancer progression. HOXA9 is upregulated in the majority of malignancies and drives cancer progression by regulating multiple signaling mechanisms. Hence, HOXA9 could be a reliable diagnostic indicator and a potential therapeutic candidate for solid cancer types.
Methods of intducing an immune response which protects a susceptible animal subject from lethal infection with  Bacillus anthracis  ( B. anthracis ) are provided. One method comprises administering  B. anthracis  lethal factor (LF) or an immunogenic fragment thereof to the subject. A second method comprises administering LF or an immunogenic fragment thereof and the  B anthracis  protective antigen (PA) to the subject. A third method comprises administering a polynucleotide which encodes  B. anthracis  LF or an immunogenic fragment thereof to the subject. A fourth method comprises administering a polynucleotide which encodes LF or an immunogenic fragment thereof and a polynucleotide which encodes the  B. anthracis  PA to the subject. The present invention also relates to a protein or peptide based-immunogenic composition for preparing a vaccine which is capable of prophylactically protecting a subject against lethal effects of infection with  B. anthracis.
The precise link between inflammation and pathogenesis of myelodysplastic syndrome (MDS) is yet to be fully established. We developed a novel method to measure ASC/NLRP3 protein specks which are specific for the NLRP3 inflammasome only. We combined this with cytokine profiling to characterise various inflammatory markers in a large cohort of patients with lower risk MDS in comparison to healthy controls and patients with defined autoinflammatory disorders (AIDs). The ASC/NLRP3 specks were significantly elevated in MDS patients compared to healthy controls (p < 0.001) and these levels were comparable to those found in patients with AIDs. The distribution of protein specks positive only for ASC was different to ASC/NLRP3 ones suggesting that other ASC-containing inflammasome complexes might be important in the pathogenesis of MDS. Patients with MDS-SLD had the lowest levels of interleukin (IL)-1β, tumour necrosis factor (TNF), IL-23, IL-33, interferon (IFN) γ and IFN-α2, compared to other diagnostic categories. We also found that inflammatory cytokine TNF was positively associated with MDS progression to a more aggressive form of disease and IL-6 and IL-1β with time to first red blood cell transfusion. Our study shows that there is value in analysing inflammatory biomarkers in MDS, but their diagnostic and prognostic utility is yet to be fully validated.
The thromboembolic and ischemic risks were assessed in 352 bleeding subjects who received ANDEXXA. Of the 63 subjects who experienced a thrombotic event, the median time to first event was 7 days, and 21 subjects experienced the event within the first three days. A total of 63 (18%) experienced 88 thromboembolic or ischemic events. Of the 352 subjects who received ANDEXXA, 223 received at least one anticoagulation dose within 30 days after treatment. Of these 223, 18 subjects (8%) had a thrombotic event and/or ischemic event after resumption.

Monitor subjects treated with ANDEXXA for signs and symptoms of arterial and venous thromboembolic events, ischemic events, and cardiac arrest. To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following treatment with ANDEXXA.

The safety of ANDEXXA has not been evaluated in subjects who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to the life-threatening bleeding event requiring treatment with ANDEXXA. Safety of ANDEXXA also has not been evaluated in subjects who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within seven days prior to the bleeding event.
FIELD: genetic engineering, molecular biology, biochemistry. SUBSTANCE: invention relates to DNA sequence encoding enzyme endo-1,3(4)-β-glucanase eliciting ability to cleave 1,3-β-D-glycoside linkages in structure of β--glucanes. This DNA sequence is prepared and sequenced as result of screening cDNA-library from Trichoderma harzianum. Invention proposes recombinant vectors containing the prepared DNA sequence and providing its expression in yeast cells. In culturing strains of Aspergillus sp. transformed with the constructed expression vector recombinant endo-1,3(4)-β-glucanase is obtained and its physical-chemical and catalytical indices of enzyme are determined that allows its using in processes involving disruption of cellular walls of many bacterial and plant producers. Invention can be used in biotechnological processes and in microbiological industry. EFFECT: improved preparing method of enzyme, valuable properties. 15 cl, 6 dwg, 2 tbl, 12 ex
Participants who allocate to the intervention group will receive regular smoking cessation training program messages by professional team. One to six messages will be sent per day for 8 weeks. Hand copy of behavioral and pharmacotherapy interventions manual will send to each HSP by mail after randomization. One to three messages will be sent per week until the end of the 1-year follow-up. They will also be encouraged to communicate the experience of using behavioral and pharmacotherapy interventions in their group.
PURPOSE: To obtain the subject product consisting of a specific constitution, CO2 and an undissolvable compressed gas as propellants, capable of favorably retaining its spraying status to the last by making the best use of the advantages of both the CO2 as the dissolvable compressed gas and the undissolvable compressed gas. CONSTITUTION: (A) A stock solution, i.e., an aqueous solution or an alcoholic aqueous solution, containing an active ingredient or surfactant, (B) a carbonate or bicarbonate (pref. sodium carbonate or sodium bicarbonate) and (C) an organic or inorganic acid (pref. citric acid or hydrochloric acid), are put into an aerosol vessel followed by sealing and then pressurizing the vessel with an undissolvable compressed gas (e.g. N2 , helium), thus obtaining the objective product. Specifically, this product is obtained by the following procedure: either of the component B or C is incorporated, in advance, in the component A, and the other is then incorporated in the form of e.g. a water-soluble capsule in the component A. It is recommended that the undissolvable compressed gas be filled immediately after sealing the vessel.  It is preferable that the pressure of the gas inside the vessel is adjusted to 3.5-7.8kg/cm<2> at normal temperatures.
This study will assess the efficacy of HIV treatment provided in accordance with the Malian National HIV Treatment Program. The Malian National HIV Treatment Program uses fixe dose coninaison (FDC) therapy, and this study will use a historical comparison from an African country in which the same generic antiretoviral are used. Virologic responses of patients enrolled in the Malian national program will be determined and, in a non-inferiority design, compared to these historical controls. The study will also establish the feasibility of doing frequent HIV virologic monitoring in this setting.

Viral RNA and CD4 T-cell count monitoring will be performed for HIV-infected persons seen at study sites. All clinical decision-making and prescription will occur outside of the protocol. Decisions about whether antiretroviral therapy is appropriate, the prescription of antiretroviral therapy, and the monitoring of treatment will be done by Malian health-care providers outside of the scope of the protocol. Viral RNA monitoring will be used to assess the endpoint of viral RNA suppression below the limit of detection (50 copies/mL).
Pokemon Go is a location-based reality mobile game for iOS and Android devices developed by Niantic. Making use of GPS and the camera of compatible devices, the game allows players to capture virtual creatures, called Pokemon, who appear on cellphone screens as though in the real world. In order to search and capture the Pokemon, the players needs to go out and become more active. For this reason, the game has great potential to promote physical activity. Nevertheless, there has no study evaluating the potential impact of Pokemon Go on physical activity. The investigator proposes a retrospective online survey. Participants are instructed to enter data of their daily physical activity as reported in iPhone Health App. Number of "Steps" and % greater than 10,000 steps/day will be compared before and after installing the Pokemon Go app.
BACKGROUND: Cellular senescence, macrophages infiltration, and vascular smooth muscle cells (VSMCs) osteogenic transdifferentiation participate in the pathophysiology of vascular calcification in chronic kidney disease (CKD). Senescent macrophages are involved in the regulation of inflammation in pathological diseases. In addition, senescent cells spread senescence to neighboring cells via Interferon-induced transmembrane protein3 (IFITM3). However, the role of senescent macrophages and IFITM3 in VSMCs calcification remains unexplored.
AIMS: To explore the hypothesis that senescent macrophages contribute to the calcification and senescence of VSMCs via IFITM3.
METHODS: Here, the macrophage senescence model was established using Lipopolysaccharides (LPS). The VSMCs were subjected to supernatants from macrophages (MCFS) or LPS-induced macrophages (LPS-MCFS) in the presence or absence of calcifying media (CM). Senescence-associated β-galactosidase (SA-β-gal), Alizarin red (AR), immunofluorescent staining, and western blot were used to identify cell senescence and calcification.
RESULTS: The expression of IFITM3 was significantly increased in LPS-induced macrophages and the supernatants. The VSMCs transdifferentiated into osteogenic phenotype, expressing higher osteogenic differentiation markers (RUNX2) and lower VSMCs constructive makers (SM22α) when cultured with senescent macrophages supernatants. Also, senescence markers (p16 and p21) in VSMCs were significantly increased by senescent macrophages supernatants treated. However, IFITM3 knockdown inhibited this process.
CONCLUSIONS: Our study showed that LPS-induced senescence of macrophages accelerated the calcification of VSMCs via IFITM3. These data provide a new perspective linking VC and aging, which may provide clues for diagnosing and treating accelerated vascular aging in patients with CKD.